The effect of maternal scent-infused blanket on the stress level, crying duration and physiological parameters of premature newborns.

J Matern Fetal Neonatal MedMay 3, 2026 (epub)
Clinical ResearchPediatrics

Shahla Shafaati Laleh, Sevil Inal, Mojgan Mirghafourvand

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed the impact of a maternal scent-infused blanket on stress levels, crying duration, and physiological parameters in 69 premature infants in the NICU. The results indicated that the maternal scent group had significantly lower stress scores and crying durations compared to the unscented and control groups (p < 0.001).

Key findings

  • Maternal scent-infused blanket group had lower Newborn Stress Scale scores compared to other groups (p < 0.001).
  • Crying duration was significantly shorter in the maternal scent group than in the unscented and control groups (p < 0.001).
  • Heart rate and oxygen saturation showed significant differences among groups during exposure (p < 0.001).

Why it matters

The findings suggest that maternal scent can be a simple, non-pharmacological intervention to help reduce stress and crying in premature infants, potentially enhancing their comfort and well-being in the NICU.

Source

Published in J Matern Fetal Neonatal Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.